Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of 20(S)-ginsenoside Rh2 compound in preparing anti-fatigue medicament

A technology of ginsenosides and compounds is applied in the application field of cancer-related fatigue drugs, which can solve the problems of unrelieved fatigue and lack of fatigue.

Inactive Publication Date: 2009-12-30
上海药谷药业有限公司
View PDF1 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For the treatment of cancer-related fatigue, there is currently a lack of effective drugs and methods. Only passive psychological adjustment or administration of hormones (such as corticosteroids, progesterone, androgen), stimulants and other drugs, but most of the fatigue does not change. get relief

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of 20(S)-ginsenoside Rh2 compound in preparing anti-fatigue medicament
  • Application of 20(S)-ginsenoside Rh2 compound in preparing anti-fatigue medicament
  • Application of 20(S)-ginsenoside Rh2 compound in preparing anti-fatigue medicament

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0172] Preparation of 20(S)-ginsenoside Rh2 ordinary capsules

[0173] Prescription: 20(S)-Ginsenoside Rh2 25mg

[0174] Lactose 170mg

[0175] Carboxymethyl Starch Sodium 5mg

[0176]5% povidone (K30) in 70% ethanol solution

[0177] Take 20(S)-ginsenoside Rh2, lactose, and sodium carboxymethyl starch through a 80-mesh sieve and mix evenly, add 5% povidone K30 in 70% ethanol solution to make a soft material, pass through a 40-mesh sieve to granulate. 50 ~ 60 ℃ oven blast drying. The dry granules are sieved through a 40-mesh sieve. Fill No. 1 capsules according to the prescribed amount, each containing 20(S)-ginsenoside Rh2 25mg.

Embodiment 2

[0179] Preparation of 20(S)-ginsenoside Rh2 ordinary capsules

[0180] Prescription: 20(S)-Ginsenoside Rh2 25mg

[0181] Microcrystalline Cellulose 170mg

[0182] Crospovidone 5mg

[0183] 5% povidone (K30) in 70% ethanol solution

[0184] Take 20(S)-ginsenoside Rh2, microcrystalline cellulose, and cross-linked povidone through a 80-mesh sieve and mix evenly, add an appropriate amount of 5% povidone K30 in 70% ethanol solution to make a soft material, pass through a 40-mesh sieve to granulate . 50 ~ 60 ℃ oven blast drying. The dry granules are sieved through a 40-mesh sieve. Fill No. 1 capsules according to the prescribed amount, each containing 20(S)-ginsenoside Rh2 25mg.

Embodiment 3

[0186] Preparation of 20(S)-ginsenoside Rh2 ordinary capsules

[0187] Prescription: 20(S)-Ginsenoside Rh2 25mg

[0188] Povidone (K30) 175mg

[0189] Proper amount of ethanol

[0190] Magnesium Stearate 1mg

[0191] Take 20(S)-ginsenoside Rh2, povidone, add appropriate amount of ethanol and heat to dissolve, put the rotary evaporator to remove ethanol, cool, pulverize, pass through a 40-mesh sieve, add the prescribed amount of magnesium stearate, and mix well. Fill No. 1 capsules according to the prescribed amount, each containing 20(S)-ginsenoside Rh2 25mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a 20(S)-ginsenoside Rh2, namely 20(S)-protopanoxadiol-3-O-beta-D-glucopyranoside compound in the field of pharmacy. The compound can confront the swimming fatigue action of tumor-bearing animals and enhance the oxygen deficit resistance and immunologic function of the tumor-bearing animals. The safety experiment shows that the compound has high safety, does not influence the central nervous system, cardiovascular system and respiratory system of animals, and has no mutagenesis function. The clinical research shows that the compound can effectively reduce the brief fatigue index BFI score of a tumor patient, improve the functional evaluation FACTIT-F score of chronic disease treatment, improve the KPS score, and simultaneously relieve Chinese medicine symptoms so as to improve the fatigue degree of the tumor patient. The compound has high safety and good anti-fatigue function under test dose, and can be used for the treatment of fatigue, in particular cancer related fatigue.

Description

technical field [0001] The present invention relates to the use of chemical substances in the field of medicine. More specifically, compound 20(S)-ginsenoside Rh2, that is, 20(S)-protopanaxadiol-3-O-β-D-glucopyranoside is used in the preparation of anti-fatigue, especially cancer-induced fatigue drugs in the application. Background technique [0002] Compound 20(S)-ginsenoside Rh2, chemical name is 3-O-β-D-glucopyranosyl-dammarane-24-ene-3β,12β,20(S)-triol, white powder shape, odorless. Soluble in methanol and ethanol, slightly soluble in ethyl acetate, almost insoluble in water, insoluble in ether and chloroform. CAS number: 78214-33-2, its structural formula is: [0003] [0004] With the increasingly fierce social competition, accelerated pace of life, and increased work pressure, the incidence of fatigue is increasing. According to literature reports, in western countries, fatigue is one of the top five reasons people go to hospital. Although fatigue does not di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P25/26A61P43/00
Inventor 惠永正吴伟泳杨翎王杰军
Owner 上海药谷药业有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com